Looking back on 2025, and where capital flowed into healthcare innovation, one thing has become increasingly clear: some of the most compelling opportunities lie in areas long underserved by both technology and investment. Maternal health is one of them. Laborie Medical Technologies’ agreement to acquire the JADA® System for $465M is not only a notable transaction by size, but a powerful signal about where unmet need, scalable innovation, and durable returns intersect in women’s health.
Maternal healthcare remains marked by profound disparities, both within the United States and globally. Postpartum hemorrhage (PPH) is still one of the leading causes of maternal mortality worldwide, disproportionately affecting women in low-resource settings and communities of color. Despite advances in obstetric care, frontline clinicians often lack fast, reliable tools to manage acute bleeding or other emergency gestational conditions. The JADA System was developed to address exactly this by providing a rapid, FDA-cleared solution for controlling abnormal postpartum bleeding at the bedside.
Laborie’s acquisition brings this technology into a platform uniquely positioned to scale it. With an established global footprint in women’s pelvic health and obstetric care, Laborie has the operational reach and commercial infrastructure needed to expand JADA’s adoption well beyond its current markets. Today, the system is already used in thousands of hospitals across more than 20 countries, a reminder that maternal health innovation is inherently global. Technologies that meaningfully improve outcomes have the potential to reach a vast and universal market.
This is what makes maternal health such a compelling economic opportunity. Solutions that address high-frequency, high-stakes clinical moments, like childbirth, benefit from consistent demand, standardized clinical pathways, and the ability to integrate into hospital workflows worldwide.
The transaction also sends a broader signal about the evolution of women’s health investing. Strategic buyers are increasingly willing to place meaningful capital behind differentiated solutions that improve outcomes and reduce systemic risk. The JADA acquisition demonstrates that innovation addressing fundamental maternal health challenges can command significant value.
We see a growing number of early-stage players in the maternal health space. Examples of emerging innovation:
Millie Clinic (Amboy Street portfolio company; Series A) — complete maternity care with midwives, OBGYNs & specialists, including prenatal care, hospital births, extended postpartum support
Mirvie (Series B) — Preeclampsia prediction and diagnostic platform
Decipher (Seed) — Wearable biosensor platform providing real-time monitoring for high-risk pregnancies
Loula (Seed) — MSO platform for Doulas, broadening access to Doula care
